

BALASSA, Leslie L.



Dr. Leslie L. Balassa, president of Lescarden, Ltd., with Dr. John F. Prudden of Columbia University College of Physicians and Surgeons. Dr. Balassa got dental patent last week. Dr. Prudden is also a director of Lescarden.

## Treatment to Stop Dental Pain Devised

New York Times 1973 Nov. 17.

*Dr. Balassa, A22A1A8*

**By STACY V. JONES**

Special to The New York Times

WASHINGTON, Nov. 16—

About one out of every 10 extracted molars leaves a dry socket that may cause excruciating pain for a week or two. A patent was granted this week for what it describes as the first treatment that stops the pain and permits normal healing. Leslie L.

**Patents** Balassa assigned  
**of the** Patent 3,772,432  
**Week** to Lescarden, Ltd.,  
a pharmaceutical  
research and de-

velopment company in Goshen, N.Y., of which he is president.

The preparation used is made of bovine cartilage and is trademarked Catrx. Mixed in a paste with a salt solution, it is inserted in a dry socket. The cartilage powder has other dental applications.

The company plans to distribute Catrx when approval is received from the Food and Drug Administration.

Dr. Balassa and Dr. John F. Prudden, associate professor of surgery at the Columbia University College of Physicians and Surgeons and a director of Lescarden, have employed Catrx for more than 10 years in research on methods of healing dry sockets and other wounds. Dr. Balassa has a number of patents in related fields.

Besides dental uses, Catrx is recommended for treatment of psoriasis.

*Patent .SK-SZEGED.NU*

*New York Times 1951*

